B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the hot stocks to buy with huge upside potential. On October 10, B.
Ovid Therapeutics Inc. (OVID)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 2,018,024 | $2,623,431 | -4% | 0% |
| 2. | Sio Capital Michael Castor | 1,427,495 | $1,855,744 | -37% | 0.47% |
| 3. | Driehaus Capital Richard Driehaus | 1,400,191 | $1,820,248 | 0.01% | |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,350,000 | $1,755,000 | +18% | 0% |
| 5. | Ikarian Capital Neil Shahrestani | 1,095,574 | $1,424,247 | 0.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.73 | 6,810 | $4,971.30 | 34,935 | 2025-01-27 | Filing | |
| $2.76 | 18,248 | $50,364.48 | 3,616,715 | 2024-03-18 | Filing | |
| $5.84 | 8,488 | $49,569.92 | 5,792,530 | 2020-08-28 | Filing | |
| $2.50 | 2,000,000 | $5,000,000.00 | 5,750,000 | 2019-10-08 | Filing | |
| $2.50 | 60,000 | $150,000.00 | 4,736,529 | 2019-10-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.56 | 5,279 | $2,956.24 | 73,406 | 2025-02-26 | Filing | |
| $0.56 | 3,902 | $2,185.12 | 67,973 | 2025-02-26 | Filing | |
| $2.15 | 17,344 | $37,289.60 | 0 | 2022-09-12 | Filing | |
| $3.71 | 34,017 | $126,203.07 | 726,823 | 2021-07-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,531,996 | $9,791,595 | 59.82% | |
| 2. | 2,820,813 | $3,667,058 | 0% | |
| 3. | 2,650,000 | $3,445,000 | 0.3% | |
| 4. | 1,106,638 | $1,438,629 | 0.03% | |
| 5. | 924,576 | $1,201,949 | 0% |
News See All
12 Hot Stocks to Buy with Huge Upside Potential
On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.
Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target
Ovid Therapeutics Inc. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc.
8 Best US Stocks Under $10 to Invest in
Everyone seeks a stock that has good upside potential, but a stock that is cheap and has good prospects - that’s what a steal deal looks like.
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best penny stocks under $1 to buy now. On June 25, Ovid Therapeutics announced a definitive agreement with Immedica Pharma AB.
12 Best Penny Stocks Under $1 to Buy Now
On July 18, Greg Tuorto of Goldman Sachs joined CNBC's 'Closing Bell' to state that the small-cap market is starting to show signs of life.
5 Oversold Biotech Stocks To Buy Right Now
In this article, we will be taking a look at 5 oversold biotech stocks to buy right now.
20 Countries With Highest Rate of Epilepsy
In this article, we will take a detailed look at the 20 countries with the highest rates of epilepsy with insights into number of epilepsy cases by country and population.
5 Best Biotech Stocks to Buy Under $10
Ovid Therapeutics Inc. (NASDAQ:OVID) is an emerging biotech company that designs therapies for epilepsies, seizure-related disorders, and neurological disorders.
10 Best Biotech Stocks Under $10
In this article, we will look at the 10 best biotech stocks under $10.
Hedge Fund Resource Center Billionaire Hedge Funds
